Ambarella Inc: Form 10-Q for the period ended Oct 31, 2023
Filed with the SEC on Dec 8, 2023 and accepted by EDGAR at Dec 8, 2023, 14:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-10-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-08-01 to 2023-10-31 | $50.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-02-01 to 2023-10-31 | $174.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-08-01 to 2023-10-31 | $20.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2023-02-01 to 2023-10-31 | $68.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-08-01 to 2023-10-31 | $30.0m | us-gaap:GrossProfit |
| Gross profit | 9 months2023-02-01 to 2023-10-31 | $106.0m | us-gaap:GrossProfit |
| Research and development | 3 months2023-08-01 to 2023-10-31 | $53.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-02-01 to 2023-10-31 | $163.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-08-01 to 2023-10-31 | $18.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2023-02-01 to 2023-10-31 | $55.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-08-01 to 2023-10-31 | −$42.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-02-01 to 2023-10-31 | −$112.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-08-01 to 2023-10-31 | $1.6m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-02-01 to 2023-10-31 | −$113.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-08-01 to 2023-10-31 | −$41.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-02-01 to 2023-10-31 | −$108.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-08-01 to 2023-10-31 | −$1.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-02-01 to 2023-10-31 | −$2.74 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-08-01 to 2023-10-31 | −$1.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-02-01 to 2023-10-31 | −$2.74 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-08-01 to 2023-10-31 | 40,053,251 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-02-01 to 2023-10-31 | 39,710,248 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-02-01 to 2023-10-31 | $23.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-02-01 to 2023-10-31 | $10.0m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2023-10-31 | $143.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-10-31 | $279.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-10-31 | $684.6m | us-gaap:Assets |
| Current liabilities | At period end2023-10-31 | $75.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-10-31 | $92.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-10-31 | $591.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-068983. Last ingested by Listed: Oct 30, 2026, 13:39 ET. Listed shows no prices and gives no investment advice.